Download PDF
Digestive Disease Interventions 2019; 03(04): 263-269
DOI: 10.1055/s-0039-3400498
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Role of Interventional Radiology in the Pretransplant Management of Hepatocellular Carcinoma and Portal Vein Thrombosis

Karen Shmelev
1   Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, Illinois
,
Bartley Thornburg
1   Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

15 May 2019

15 October 2019

Publication Date:
21 November 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and is currently the leading indication for liver transplantation in the United States. Liver transplantation may provide a curative option for patients with HCC, but some present outside of the transplant criteria. Additionally, as the criteria for liver transplant eligibility in HCC are expanded and the incidence of disease increases, waitlist times are becoming progressively longer, which increases the chance of a patient suffering from disease progression while awaiting an organ becoming ineligible for transplant. Multiple studies have demonstrated the successful use of locoregional therapies, including trans-arterial chemoembolization and trans-arterial radioembolization, in downstaging HCC to within transplant criteria, as well as in preventing progression of disease in patients already listed for transplant. Cirrhotic patients also commonly develop portal vein thrombosis (PVT), which is a contraindication to transplantation at many centers. PVT can lead to worsened outcomes after transplant depending on the type of portal venous reconstruction that is performed. The purpose of this article is to discuss the integral role of interventional radiology in the care of these patients, including the role of transarterial therapies in the pretransplant treatment of HCC and the use of endovascular techniques to recanalize thrombosed portal veins in order to establish or maintain transplant eligibility.

Keywords

bridging hepatocellular carcinoma - downstaging hepatocellular carcinoma - portal vein recanalization - liver transplantation

Disclaimer

Since Dr. Bartley Thornburg is a Section Editor of the journal, Dr. Zach Berman and Dr. Jeet Minocha served as ad hoc Section Editors for this manuscript.


 

  • References

  • 1 European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
    CrossrefPubMedGoogle Scholar
  • 2 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013; 47 (Suppl): S2-S6
    CrossrefPubMedGoogle Scholar
  • 3 Giannini EG, Farinati F, Ciccarese F. , et al; Italian Liver Cancer (ITA.LI.CA) Group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61 (01) 184-190
    CrossrefPubMedGoogle Scholar
  • 4 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (03) 329-338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Yang JD, Larson JJ, Watt KD. , et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin Gastroenterol Hepatol 2017; 15 (05) 767-775.e3
    CrossrefPubMedGoogle Scholar
  • 6 Mazzaferro V, Regalia E, Doci R. , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 7 Yao FY, Ferrell L, Bass NM. , et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
    CrossrefPubMedGoogle Scholar
  • 8 Duffy JP, Vardanian A, Benjamin E. , et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246 (03) 502-509 , discussion 509–511
    CrossrefPubMedGoogle Scholar
  • 9 Pillai A, Couri T, Charlton M. Liver allocation policies in the USA: past, present, and the future. Dig Dis Sci 2019; 64 (04) 985-992
    CrossrefPubMedGoogle Scholar
  • 10 Habibollahi P, Hunt S, Gade T. , et al. The impact of bridging LRT on survival in patients listed for liver transplantation. Cardiovasc Intervent Radiol 2018; 41 (01) 112-119
    CrossrefPubMedGoogle Scholar
  • 11 Bruix J, Sherman M. ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022
    CrossrefPubMedGoogle Scholar
  • 12 Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30 (06) 1434-1440
    CrossrefPubMedGoogle Scholar
  • 13 Yao FY, Bass NM, Nikolai B. , et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9 (07) 684-692
    CrossrefPubMedGoogle Scholar
  • 14 Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013; 30 (01) 3-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Lewandowski RJ, Mulcahy MF, Kulik LM. , et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010; 255 (03) 955-965
    CrossrefPubMedGoogle Scholar
  • 16 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (02) 429-442
    CrossrefPubMedGoogle Scholar
  • 17 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19 (43) 7515-7530
    CrossrefPubMedGoogle Scholar
  • 18 Graziadei IW, Sandmueller H, Waldenberger P. , et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9 (06) 557-563
    CrossrefPubMedGoogle Scholar
  • 19 Maddala YK, Stadheim L, Andrews JC. , et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10 (03) 449-455
    CrossrefPubMedGoogle Scholar
  • 20 Millonig G, Graziadei IW, Freund MC. , et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13 (02) 272-279
    CrossrefPubMedGoogle Scholar
  • 21 Hayashi PH, Ludkowski M, Forman LM. , et al. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 2004; 4 (05) 782-787
    CrossrefPubMedGoogle Scholar
  • 22 Chapman WC, Majella Doyle MB, Stuart JE. , et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008; 248 (04) 617-625
    CrossrefPubMedGoogle Scholar
  • 23 Otto G, Herber S, Heise M. , et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12 (08) 1260-1267
    CrossrefPubMedGoogle Scholar
  • 24 Ravaioli M, Grazi GL, Piscaglia F. , et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8 (12) 2547-2557
    CrossrefPubMedGoogle Scholar
  • 25 Yao FY, Kerlan Jr RK, Hirose R. , et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48 (03) 819-827
    CrossrefPubMedGoogle Scholar
  • 26 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013; 11 (06) 604-611 , quiz e43–e44
    CrossrefPubMedGoogle Scholar
  • 27 Hickey RM, Lewandowski RJ, Salem R. Yttrium-90 radioembolization for hepatocellular carcinoma. Semin Nucl Med 2016; 46 (02) 105-108
    CrossrefPubMedGoogle Scholar
  • 28 Salem R, Lewandowski RJ, Atassi B. , et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16 (12) 1627-1639
    CrossrefPubMedGoogle Scholar
  • 29 Kulik LM, Atassi B, van Holsbeeck L. , et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94 (07) 572-586
    CrossrefPubMedGoogle Scholar
  • 30 Ettorre GM, Levi Sandri GB, Laurenzi A. , et al. Yttrium-90 radioembolization for hepatocellular carcinoma prior to liver transplantation. World J Surg 2017; 41 (01) 241-249
    CrossrefPubMedGoogle Scholar
  • 31 Abdelfattah MR, Al-Sebayel M, Broering D, Alsuhaibani H. Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience. Transplant Proc 2015; 47 (02) 408-411
    CrossrefPubMedGoogle Scholar
  • 32 Tohme S, Sukato D, Chen HW. , et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol 2013; 24 (11) 1632-1638
    CrossrefPubMedGoogle Scholar
  • 33 Lewandowski RJ, Kulik LM, Riaz A. , et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9 (08) 1920-1928
    CrossrefPubMedGoogle Scholar
  • 34 Salem R, Gordon AC, Mouli S. , et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
    CrossrefPubMedGoogle Scholar
  • 35 Werner JD, Frangakis C, Ruck JM. , et al. Neoadjuvant transarterial chemoembolization improves survival after liver transplant in patients with hepatocellular carcinoma. Exp Clin Transplant 2019; 17 (05) 638-643
    PubMedGoogle Scholar
  • 36 Kallini JR, Gabr A, Ali R. , et al. Pretransplant intra-arterial liver-directed therapy does not increase the risk of hepatic arterial complications in liver transplantation: a single-center 10-year experience. Cardiovasc Intervent Radiol 2018; 41 (02) 231-238
    CrossrefPubMedGoogle Scholar
  • 37 Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis?. J Hepatol 2009; 51 (04) 632-634
    CrossrefPubMedGoogle Scholar
  • 38 Yerdel MA, Gunson B, Mirza D. , et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000; 69 (09) 1873-1881
    CrossrefPubMedGoogle Scholar
  • 39 Hibi T, Nishida S, Levi DM. , et al. When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. Ann Surg 2014; 259 (04) 760-766
    CrossrefPubMedGoogle Scholar
  • 40 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol 2016; 64 (01) 179-202
    CrossrefPubMedGoogle Scholar
  • 41 Villa E, Cammà C, Marietta M. , et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253-1260.e4
    CrossrefPubMedGoogle Scholar
  • 42 Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26 (01) 23-29
    CrossrefPubMedGoogle Scholar
  • 43 Zocco MA, Di Stasio E, De Cristofaro R. , et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51 (04) 682-689
    CrossrefPubMedGoogle Scholar
  • 44 Habib A, Desai K, Hickey R. , et al. Portal vein recanalization-transjugularintrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol 2015; 26 (04) 499-506
    CrossrefPubMedGoogle Scholar
  • 45 Salem R, Vouche M, Baker T. , et al. Pretransplant portal vein recanalization-transjugular intrahepatic portosystemic shunt in patients with complete obliterative portal vein thrombosis. Transplantation 2015; 99 (11) 2347-2355
    CrossrefPubMedGoogle Scholar
  • 46 Thornburg B, Desai K, Hickey R. , et al. Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: technical considerations. Tech Vasc Interv Radiol 2016; 19 (01) 52-60
    CrossrefPubMedGoogle Scholar
  • 47 Kallini JR, Gabr A, Kulik L. , et al. Noncirrhotic complete obliterative portal vein thrombosis: novel management using trans-splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization. Hepatology 2016; 63 (04) 1387-1390
    CrossrefPubMedGoogle Scholar
  • 48 Thornburg B, Desai K, Hickey R. , et al. Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol 2017; 28 (12) 1714-1721.e2
    CrossrefPubMedGoogle Scholar